• 1
    Trabandt A, Gay RE, Gay S. Oncogene activation in rheumatoid synovium. APMIS 1992; 100:861 75.
  • 2
    Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64:235 48.
  • 3
    Marshall CJ. Tumor suppressor genes. Cell 1991; 64:313 26.
  • 4
    Harris CC & Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New England J Med 1993; 329:1318 27.
  • 5
    Clarke AR, Purdie CA, Harrison DJ et al Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362:849 52.
  • 6
    Dittmer D, Pati S, Zambetti G et al Gain of function mutations in p53. Nature Genet 1993; 4:42 46.
  • 7
    Oren M, Maltzman W, Levine AJ. Posttranslational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981; 1:101 10.
  • 8
    Lu X & Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993; 75:765 78.
  • 9
    Jonason AS, Kunala S, Price GJ et al Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 93:14025 9.
  • 10
    Tadini G, Cerri A, Crosti L et al p53 and oncogene expression in psoriasis. Acta Derm Venereol 1989; 146:33 35.
  • 11
    Molès JP, Theillet C, Basset-Seguin N et al Mutation of the tumor suppressor gene TP53 is not detected in psoriatic skin. Invest Dermatol 1993; 101:100 2.
  • 12
    Kovacs B, Patel A, Hershey JN et al Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 1997; 40:980 2.
  • 13
    Arnett FC, Edworthy SM, Bloch DA et al The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315 24.
  • 14
    Togushida J, Yamagushi T, Ritchie B et al Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52:6194 9.
  • 15
    Orita M, Iwahana H, Kanazawa H et al Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformations polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766 70.
  • 16
    Cordell JF, Falini B, Erber WN et al Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219 29.
  • 17
    Mazars GR, Portier M, Zhang XG et al Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7:1015 8.
  • 18
    Gaidano G, Ballerini P, Gong JZ et al P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88:5413 7.
  • 19
    Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990; 5:945 52.
  • 20
    Dooley S, Helitzka I, Hanselmann R et al Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Ann Rheum Dis 1996; 55:298 304.
  • 21
    Firestein GS, Nguyen K, Aupperle KR et al Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996; 149:2143 51.
  • 22
    Watanabe-Fukunaga R, Brannan CI, Copeland NG et al Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314 7.
  • 23
    Chu JL, Drappa J, Parnassa A et al The defect of Fas mRNA expresion in MRL-lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 1993; 178:723 30.
  • 24
    Mountz JD, Wu J, Cheng J et al Autoimmune diseases. A problem of defective apoptosis. Arthritis Rheum 1994; 37:1415 20.
  • 25
    Nakajima T, Aono H, Hasunuma T et al Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995; 38:485 91.
  • 26
    Martinez-Delgado B, Robledo M, Arranz E et al Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol 1997; 55:1 8.